Review of the RECOVERY Study on Sotrovimab for COVID-19, Mixed Results

The RECOVERY Collaborative Group led by Prof. Peter W. Horby and Prof. Martin J. Landray from the University of Oxford investigated the efficacy of sotrovimab, a monoclonal antibody (mAb) developed by GlaxoSmithKline and Vir Biotechnology, in hospitalized COVID-19 patients with pneumonia. Their hypothesis centered on whether sotrovimab could reduce 28-day mortality, particularly among patients with high SARS-CoV-2 nucleocapsid antigen levels&mdash;a biomarker of active viral replication.
Study Design